Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Book

Hyperkalemia

In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan.
.
Affiliations
Free Books & Documents
Book

Hyperkalemia

Leslie V. Simon et al.
Free Books & Documents

Excerpt

Hyperkalemia is defined as a serum or plasma potassium level above the upper limits of normal, usually greater than 5.0 mEq/L to 5.5 mEq/L. While mild hyperkalemia is usually asymptomatic, high potassium levels may cause life-threatening cardiac arrhythmias, muscle weakness, or paralysis. Symptoms usually develop at higher levels, 6.5 mEq/L to 7 mEq/L, but the rate of change is more important than the numerical value. Patients with chronic hyperkalemia may be asymptomatic at increased levels, while patients with dramatic, acute potassium shifts may develop severe symptoms at lower ones. Infants have higher baseline levels than children and adults.

Pseudohyperkalemia is quite common and represents a false elevation in measured potassium due to specimen collection, handling, or other causes. Hyperkalemia should always be confirmed before aggressive treatment in cases where the serum potassium is elevated without explanation. True hyperkalemia may be caused by increased potassium intake, transcellular movement of intracellular potassium into the extracellular space, and decreased renal excretion. The urgency of therapy depends on symptoms, serum levels, and causes of hyperkalemia.

PubMed Disclaimer

Conflict of interest statement

Disclosure: Leslie Simon declares no relevant financial relationships with ineligible companies.

Disclosure: Muhammad Hashmi declares no relevant financial relationships with ineligible companies.

Disclosure: Mitchell Farrell declares no relevant financial relationships with ineligible companies.

References

    1. Lytvyn Y, Godoy LC, Scholtes RA, van Raalte DH, Cherney DZ. Mineralocorticoid Antagonism and Diabetic Kidney Disease. Curr Diab Rep. 2019 Jan 23;19(1):4. - PubMed
    1. Flury G. [The 'Dangerous' ECG]. Praxis (Bern 1994) 2019 Jan;108(1):45-52. - PubMed
    1. Williams SM, Killeen AA. Tumor Lysis Syndrome. Arch Pathol Lab Med. 2019 Mar;143(3):386-393. - PubMed
    1. Dunn JD, Benton WW, Orozco-Torrentera E, Adamson RT. The burden of hyperkalemia in patients with cardiovascular and renal disease. Am J Manag Care. 2015 Nov;21(15 Suppl):s307-15. - PubMed
    1. Ohkuma T, Harris K, Cooper M, Grobbee DE, Hamet P, Harrap S, Mancia G, Marre M, Patel A, Rodgers A, Williams B, Woodward M, Chalmers J, ADVANCE Collaborative Group Short-Term Changes in Serum Potassium and the Risk of Subsequent Vascular Events and Mortality: Results from a Randomized Controlled Trial of ACE Inhibitors. Clin J Am Soc Nephrol. 2022 Aug;17(8):1139-1149. - PMC - PubMed

Publication types

LinkOut - more resources